- ICH GCP
- EU Kliniske forsøgsregister
Seneste forsøg
EudraCT Number: 2004-000348-25 | Sponsor Protocol Number: D6160C00031 | Start Date: 2004-09-22 | |||||||||||
Sponsor Name: ASTRAZENECA | |||||||||||||
Full Title: GALLANT 8 - A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Added to the Th... | |||||||||||||
Medical condition: To prevent vascular disease associated with insulin resistence. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001033-41 | Sponsor Protocol Number: H6D-MC-LVFZ | Start Date: 2004-09-22 | |||||||||||
Sponsor Name: ELI LILLY | |||||||||||||
Full Title: A Randomized, Double-Blind, Parallel-Design, Placebo-Controlled Study to Evluate the Efficacy and Safety of Tadalafil (2.5 mg e 5 mg) administered once daily to men with diabetes mellitus and erect... | |||||||||||||
Medical condition: Therapy of erectile disfunction to subjects with diabetes mellitus and erectile disfunction with a 2.5 mg or 5 mg daily dosing. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001551-11 | Sponsor Protocol Number: Iloprost | Start Date: 2004-09-22 | ||||||
Sponsor Name: Lund University Hospital | ||||||||
Full Title: Behandling av förhöjt pulmonellt arteriellt tryck med inhalerad iloprost | ||||||||
Medical condition: Nyfödda barn som är i behov av respiratorvård pga RDS, mekoniumaspiration eller primär lunghypertension | ||||||||
|
||||||||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |||||||
Trial protocol: SE (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000646-20 | Sponsor Protocol Number: C04-001 | Start Date: 2004-09-21 | |||||||||||
Sponsor Name: ALEXION PHARMACEUTICALS INCORPORATED | |||||||||||||
Full Title: A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal... | |||||||||||||
Medical condition: paroxysmal nocturnal hemoglobinuria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) IE (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000805-23 | Sponsor Protocol Number: LEV102341 | Start Date: 2004-09-21 | |||||||||||
Sponsor Name: GLAXO SMITHKLINE | |||||||||||||
Full Title: A national, multicentric, randomised, controlled trial. Applications of a critical pathway using LEVOFLOXACIN for the management of patients with abnormal PSA | |||||||||||||
Medical condition: prostatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001883-39 | Sponsor Protocol Number: P02561 | Start Date: 2004-09-21 | |||||||||||
Sponsor Name: Schering Plough Reserach Institute | |||||||||||||
Full Title: Study to Evaluate the Effect of the Coadministration of SCH 497079 (a Histamine 3 [H3] Receptor Antagonist) Plus Desloratadine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis Who Ha... | |||||||||||||
Medical condition: Seasonal Allergic Rhinitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000185-12 | Sponsor Protocol Number: CELC200A2401 / 2939107 | Start Date: 2004-09-21 | |||||||||||
Sponsor Name: Orion Corporation, ORION PHARMA | |||||||||||||
Full Title: A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo® in patients with Parkinson’s disease requiring initiation... | |||||||||||||
Medical condition: Parkinson's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) SE (Completed) AT (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002249-11 | Sponsor Protocol Number: BLQ-01-003-04 | Start Date: 2004-09-20 | ||||||
Sponsor Name: BAUSCH&LOMB - IOM S.P.A. | ||||||||
Full Title: Double blind, randomized, multicenter, placebo-controlled, parallel-group design clinical trial of the efficacy and tolerability of cloriclomene hydrochloride capsules 100 mg TID in diabetic patien... | ||||||||
Medical condition: Mild to moderate non-proliferative diabetic retinopathy | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: IT (Prematurely Ended) | ||||||||
Trial results: View results |
EudraCT Number: 2004-001600-12 | Sponsor Protocol Number: F/2004/2. | Start Date: 2004-09-20 | ||||||
Sponsor Name: OMNINVEST Kft. | ||||||||
Full Title: Fluval AB Vaccine Serologic Clinical Trial | ||||||||
Medical condition: Immunization of healthy people against influenza virus infections. | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: HU (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-000838-36 | Sponsor Protocol Number: PX104.1.7-201 | Start Date: 2004-09-20 | ||||||
Sponsor Name: Pharmexa A/S | ||||||||
Full Title: A Phase II trial evaluating the immunological and clinical efficay and safety of HER-2 Protein Autovac(TM) monotherapy in patients with metastatic breast cancer | ||||||||
Medical condition: Female patients with histologically proven metastatic or locally advanced breast cancer who have HER-2 overexpression in the primary tumour and/or a metastatic lesion. | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||
Trial protocol: HU (Completed) | ||||||||
Trial results: (No results available) |